Oral suspension formulation
AssigneeUnilab Pharmatech, Ltd.
InventorsDanilo R. Venus, Eulogio C. Singh, Rita Josefina M. Santos, Ma. Joyce Bedelia B. Santos, Kennie U. Dee
Life of this patent
Estimating the term…
Abstract
An aqueous pharmaceutical suspension for oral administration of a drug, which suspension maintains its content uniformity for prolonged period.
Claims26
An aqueous pharmaceutical suspension for oral administration comprising at least one particulate drug with a density of from about 0.9 to about 1.6 g/ml and an average particle size less than about 20 μm;
- at least one suspending polymer exhibiting plastic flow with or without additional viscosity-building agents that provides a yield value to the final suspension of about 0.2 to about 15 Pa and an apparent viscosity at 100 sec−1 of at least about 50 cps;
- a liquid phase with an absolute density difference from each particulate drug compound of less than about 0.2 g/ml;
- the suspension being further characterized by a relative standard deviation of less than about 25% when tested according to the Centrifugation Test Method.
An aqueous acetaminophen suspension comprising from about 1.5 to about 10 percent by weight acetaminophen with an average particle size less than about 10 μm;
- from about 0.1 to about 0.5 percent by weight of xanthan gum;
- a liquid phase with an absolute density difference of less than about 0.05 g/ml from the particulate acetaminophen;
- the suspension being further characterized by a relative standard deviation of less than about 6% when tested according to the Centrifugation Test Method.
An aqueous rifampicin suspension comprising from about 1 to about 5 percent by weight rifampicin with an average particle size less than about 10 μm;
- from about 0.1 to about 0.5 percent by weight of xanthan gum;
- from about 0.01 to about 2 percent by weight of at least one antifoaming agent;
- from about 0.001 to about 0.5 percent by weight of at least one wetting agent;
- a liquid phase with an absolute density difference of less than about 0.05 g/ml from the particulate rifampicin;
- the suspension being further characterized by a relative standard deviation of less than about 6% when tested according to the Centrifugation Test Method.
Dependencies are inferred from the claim text.